NKGen Biotech, Inc. Common Stock
NKGN
NKGN was delisted on the 4th of March, 2025.
19 hedge funds and large institutions have $1.23M invested in NKGen Biotech, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
12% more funds holding
Funds holding: 17 → 19 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
71% less capital invested
Capital invested by funds: $4.24M → $1.23M (-$3.01M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$164K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$154K |
| 3 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$90.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$84.7K |
| 5 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
+$44.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$251K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$25.9K |
| 3 |
VF
Virtu Financial
New York
|
-$24K |
| 4 |
BlackRock
New York
|
-$13.4K |
| 5 |
HF
HRT Financial
New York
|
-$950 |
NKGN Hedge Fund Activity: Q3 2024 in Review
19 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q3 2024, worth a combined $1.23M — down 71% from $4.24M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NKGN positions and 1 closed out — a net gain of 2 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Diametric Capital, adding an estimated $164K. The largest seller was Meteora Capital, cutting an estimated $251K.
- 19 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q3 2024, up from 17 in Q2 2024.
- Funds reported $1.23M of NKGen Biotech, Inc. Common Stock stock for Q3 2024, down 71% quarter-over-quarter.
- 3 funds opened new NKGen Biotech, Inc. Common Stock positions in Q3 2024 and 1 closed out, a net change of +2 holders.
- The largest NKGen Biotech, Inc. Common Stock buyer in Q3 2024 was Diametric Capital, an estimated $164K added.
- The largest NKGen Biotech, Inc. Common Stock seller in Q3 2024 was Meteora Capital, an estimated $251K sold.
Based on aggregated 13F filings for Q3 2024.